Advances in Musculoskeletal Tissue Regeneration Using Mesenchymal Stromal/Stem Cells, Biomaterials, and Signaling Molecules: Second Edition

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Stem Cells".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 697

Special Issue Editors


E-Mail Website
Guest Editor
Department of Orthopaedics, Division of Sports Medicine, Diabetes Research Institute, Cell Transplant Center, University of Miami, Miller School of Medicine, 1450NW 10th Ave, Room 3012, Miami, FL 33136, USA
Interests: mesenchymal stem cells/multipotential stromal cells (MSCs); MSC trophic and immunomodulatory actions; MSC functionalization ex vivo; inflammation and fibrosis reversal; synovitis; osteoarthritis; regenerative sports medicine; regenerative orthopaedics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Orthopaedics, Division of Sports Medicine, University of Miami, Miller School of Medicine, 5555 Ponce de Leon, Coral Gables, FL 33146, USA
Interests: stem cell research; biomedical engineering; kinesiology; osteoarthritis; regenerative sports medicine; regenerative orthopaedics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The regeneration of musculoskeletal tissues is a serious clinical challenge, largely due to injury and disease being the leading causes of physical disability worldwide. Approved mesenchymal stromal/stem cells (MSC) and MSC products (i.e., extracellular vesicles) for stem cell-based therapy applications offer huge promise to rejuvenating musculoskeletal tissues and to triggering tissue repair and healing. In parallel, the discovery of specialised biomaterials and signalling molecules has opened novel therapeutic avenues as part of tissue engineering approaches. Presently, significant progress has been made in developing and optimizing the components of this therapeutic triad (cells, biomaterials, signalling molecules), but only a limited number of technologies have been successfully transferred into the clinical setting. Currently, efforts are focused on bringing closer basic science and cell-based product manufacturing techniques to potential clinical protocols. This Special Issue aims to present a state-of-the-art update on the use of MSC, biomaterials, and signalling molecules for musculoskeletal therapeutic applications.

We are pleased to invite you as a recognised expert in the field to contribute original articles, communications, and reviews covering the entire field of musculoskeletal regeneration research, including (but not limited to), the following:

  • MSC and biomaterial functionalisation (e.g., cell phenotype-based purification, cell priming, gene-activated matrices);
  • MSC-derived extracellular vesicle isolation and methods to reinforce their therapeutic signatures;
  • Benefits and limitations of MSC versus MSC-derived extracellular vesicles for musculoskeletal applications;
  • MSC and MSC-derived extracellular vesicle effects on immunomodulation and senescent cell clearance;
  • Potent signalling molecules to promote healing, reduce inflammation, and stimulate cellular communication;
  • Novel specialised biomaterials and scaffolds utilised to regenerate musculoskeletal tissues;
  • Microphysiological systems (organ or tissue chips), are generated according to musculoskeletal tissue engineering principles, as drug testing models.

We look forward to hearing any questions you may have and hopefully receiving your contributions.

Dr. Dimitrios Kouroupis
Dr. Thomas M. Best
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesenchymal stromal/stem cells
  • extracellular vesicles
  • biomaterials
  • signalling molecules
  • microphysiological systems
  • musculoskeletal regeneration
  • immunomodulation
  • cell therapy
  • tissue engineering

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issue

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 2861 KiB  
Article
Synovium-Derived and Bone-Derived Mesenchymal Stem/Stromal Cells from Early OA Patients Show Comparable In Vitro Properties to Those of Non-OA Patients
by Janja Zupan and Klemen Stražar
Cells 2024, 13(15), 1238; https://doi.org/10.3390/cells13151238 - 23 Jul 2024
Viewed by 508
Abstract
Degenerative disorders like osteoarthritis (OA) might impair the ability of tissue-resident mesenchymal stem/stromal cells (MSCs) for tissue regeneration. As primary cells with MSC-like properties are exploited for patient-derived stem cell therapies, a detailed evaluation of their in vitro properties is needed. Here, we [...] Read more.
Degenerative disorders like osteoarthritis (OA) might impair the ability of tissue-resident mesenchymal stem/stromal cells (MSCs) for tissue regeneration. As primary cells with MSC-like properties are exploited for patient-derived stem cell therapies, a detailed evaluation of their in vitro properties is needed. Here, we aimed to compare synovium-derived and bone-derived MSCs in early hip OA with those of patients without OA (non-OA). Tissues from three synovial sites of the hip (paralabral synovium, cotyloid fossa, inner surface of peripheral capsule) were collected along with peripheral trabecular bone from 16 patients undergoing hip arthroscopy (8 early OA and 8 non-OA patients). Primary cells isolated from tissues were compared using detailed in vitro analyses. Gene expression profiling was performed for the skeletal stem cell markers podoplanin (PDPN), CD73, CD164 and CD146 as well as for immune-related molecules to assess their immunomodulatory potential. Synovium-derived and bone-derived MSCs from early OA patients showed comparable clonogenicity, cumulative population doublings, osteogenic, adipogenic and chondrogenic potential, and immunophenotype to those of non-OA patients. High PDPN/low CD146 profile (reminiscent of skeletal stem cells) was identified mainly for non-OA MSCs, while low PDPN/high CD146 mainly defined early OA MSCs. These data suggest that MSCs from early OA patients are not affected by degenerative changes in the hip. Moreover, the synovium represents an alternative source of MSCs for patient-derived stem cell therapies, which is comparable to bone. The expression profile reminiscent of skeletal stem cells suggests the combination of low PDPN and high CD146 as potential biomarkers in early OA. Full article
Show Figures

Graphical abstract

Back to TopTop